---
category: news
title: "China’s Adagene raises $69m for cancer immunotherapies"
excerpt: "Adagene’s drug development platform relies on artificial intelligence and computational biology to engineer antibodies that ... including trials as a combination therapy with BMS’ checkpoint inhibitor Opdivo (nivolumab). Following after is ADG116, an antibody that blocks the CTLA4 receptor also targeted by BMS’ blockbuster melanoma ..."
publishedDateTime: 2020-01-09T12:08:00Z
sourceUrl: https://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
type: article
quality: 39
heat: 39
published: false

provider:
  name: pharmaphorum.com
  domain: pharmaphorum.com

topics:
  - AI
  - AI in Healthcare

images:
  - url: https://www.bing.com/th?id=ON.E2C961C78C206EBBCCB52D2828E966F7
    width: 700
    height: 400
    title: "China’s Adagene raises $69m for cancer immunotherapies"

secured: "92R3Y2g8NNiV/y5nG8WAlZq+XIQ9tJjGJ71Rgn01W2/+fKDav5fAgPsbg9gGSk+3yAy0kUcSgJ11tU4oJ5vux5ncJqubLGQEfHW0imV+Dt8wtLJJztHPy/vfmjq+zd/b2J5ydbpTQEQcpDIom/UL3QD1OedYWBTHPmcPtR52MNzSoClU6YdiGyn2Ny6nmNxk7xEVBsqW2KH8q+CT3Ueg/nzgh9gabNRvh967VXiZ4Y8xQLJQbshCzNgovnsHBtn4aSsgxbfn4Ib42R0yC/tDKA==;ucQe+qFeFgil7Ch4bSwrHg=="
---

